MedTrace Logo

CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs ("CONTINUUM")

NCT00908947 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2019-11-19

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to collect post-market confirmatory evidence of the safety and effectiveness of the Bard® LifeStent® Vascular Stent System and LifeStent® XL Vascular Stent System (together the "LifeStent® Vascular Stent System").

Conditions

  • Superficial Femoral Artery Stenosis

Interventions

DEVICE

PTA followed by placement of LifeStent® Vascular Stent

PTA followed by placement of LifeStent® Vascular Stent

Sponsors & Collaborators

  • C. R. Bard

    lead INDUSTRY

Principal Investigators

  • Jeffrey P Carpenter, MD · The Cooper Health System

  • Mark D Mewissen, MD · Wake Forest University Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2018-09-18
Completion
2018-09-19
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00908947 on ClinicalTrials.gov